Predicting ADME properties and side effects: The BioPrint approach

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 4, 2003, Pages 470-480

  Krejsa, Cecile M ^a   Horvath, Dragos ^b   Rogalski, Sherri L ^a   Penzotti, Julie E ^a   Mao, Boryeu ^a   Barbosa, Frédérique ^b   Migeon, Jacques C ^a  

^a Cerep Inc   (United States)

^b CEREP   (France)

Author keywords

Adverse drug reactions; Computational biology; Computational chemistry; Drug design; Pharmacological profiling; Structure activity relationship

Indexed keywords

ALPHAPRODINE; ANALGESIC AGENT; ANILERIDINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPRURITIC AGENT; ANTIVERTIGO AGENT; ANXIOLYTIC AGENT; BENPERIDOL; DEXBROMPHENIRAMINE; DROPERIDOL; HALOPERIDOL; ISOXSUPRINE; KETANSERIN; LEVOCABASTINE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PHENTOLAMINE MESYLATE; PIRENPERONE; QUININE SULFATE; RISPERIDONE; SPIPERONE; TRANQUILIZER; TRAZODONE; TRIFLUPERIDOL; TRIPELENNAMINE; UNINDEXED DRUG; VASODILATOR AGENT;

ABSORPTION; AKATHISIA; BINDING ASSAY; CATATONIA; CONSTIPATION; CONVULSION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DYSKINESIA; DYSTONIA; EEG ABNORMALITY; ENZYME ASSAY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPOTENSION; HYPOTHERMIA; MOLECULAR MODEL; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OCULOGYRIC CRISIS; OPISTHOTONUS; ORTHOSTATIC HYPOTENSION; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; TORTICOLLIS; URINE RETENTION; XEROSTOMIA;

ANIMALS; ARTIFICIAL INTELLIGENCE; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP2D6; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0043031339     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Clark DE, Grootenhuis PD: Progress in computational methods for the prediction of ADMET properties. Curr Opin Drug Discovery Dev (2002) 5(3):382-390. A thorough review of computational methods to predict ADMET.
2. Podlogar BL, Muegge I, Brice LJ: Computational methods to estimate drug development parameters. Curr Opin Drug Discovery Dev (2001) 4(1):102-109. An overview of the literature on computational methods that predict ADMET.
3. Mitchell T, Showell GA: Design strategies for building drug-like chemical libraries. Curr Opin Drug Discovery Dev (2001) 4(3):314-318. A good overview on the state of ADME prediction.
4. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA: Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods (2000) 44(1):313-324. A historical overview of in silico ADME prediction from an in vitro approach.
5. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH: Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods (2000) 44(1):251-272. This article reviews the evolution of computational ADME prediction.
6. Egan WJ, Merz KM, Baldwin JJ: Prediction of drug absorption using multivariate statistics. J Med Chem (2000) 43(21):3867-3877.
7. Todeschini R, Consonni V: Handbook of Molecular Descriptors. Mannhold R, Kubinyi H, Timmerman H (Eds), Wiley-VCH Verlag GmbH, Weinheim, Germany (2000).
8. Mason JS, Morize I, Menard PR, Cheney DL, Hulme C, Labaudiniere RF: New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J Med Chem (1999) 42(17):3251-3264. Four-point pharmacophore bit strings are able to capture chirality-dependent 3D-pharmacophore pattern information.
9. Mason JS, Cheney DL: Library design and virtual screening using multiple 4-point pharmacophore fingerprints. Pacific Symp Biocomput (2000)5:576-587.
10. Sheridan RP, Kearsley SK: Why do we need so many chemical similarity search methods? Drug Disc Today (2002) 7(17):903-911.
11. Feuston BP, Miller MD, Culberson JC, Nachbar RB, Kearsley SK: Comparison of knowledge-based and distance geometry approaches for generation of molecular conformations. J Chem Inf Comput Sc (2001) 41(3):754-763. Describes a knowledge-based approach to generate molecular conformations, using physicochemical properties to facilitate early drug development.
12. Horvath D: A virtual screening approach applied to the search for trypanothione reductase inhibitors. J Med Chem (1997) 40(15):2412-2423.
13. Horvath D: High-throughput conformational sampling and fuzzy similarity metrics: A novel approach to similarity searching and focused combinatorial library design and its role in the drug discovery laboratory. In: Combinatorial Library Design and Evaluation: Principles, Software, Tools and Applications in Drug Discovery. Ghose AK, Viswanadhan VN (Eds), Marcel Dekker, New York, NY, USA (2001):429-472. The development of pharmacophore-based fuzzy molecular descriptors for high-throughput library design and QSAR analysis is presented.
14. So SS, Karplus M: Evolutionary optimization in quantitative structure-activity relationship: An application of genetic neural networks. J Med Chem (1996) 39(7):1521-1530. A genetic algorithm and an artificial neural network are combined for QSAR studies.
15. Rogers D, Hopfinger AJ: Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci (1994) 34(4):854-866.
16. Besalu E, Girones X, Amat L, Carbo-Dorca R: Molecular quantum similarity and the fundamentals of QSAR. Acc Chem Res (2002) 35(4):289-295.
17. Artursson P, Palm K, Luthman K: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev (2001) 46(1-3):27-43.
18. Yamashita F, Fujiwara S, Hashida M: The 'latent membrane permeability' concept: QSPR analysis of inter/intralaboratory variable Caco-2 permeability. J Chem Inf Comput Sci (2002) 42(2):408-413.
19. Artursson P: Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci (1990) 79(6):476-482. This paper and reference [20] describe the use of Caco2 cells to model intestinal permeabilily.
20. Artursson P, Magnusson C: Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci (1990) 79(7):595-600. This paper and reference [19] describe the use of Caco2 cells to model intestinal permeability.
21. Kim RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev (2002) 34(1-2):47-54.
22. Bohets H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K: Strategies for absorption screening in drug discovery and development. Curr Top Med Chem (2001) 1(5):367-383.
23. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem (1998) 41(27):5382-5392. A good overview of the relationship between various melecular descriptors and transport of drugs across the intestinal epithelium.
24. Norris DA, Leesman GD, Sinko PJ, Grass GM: Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release (2000) 65(1-2):55-62.
25. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci (1998) 6(4):313-319. An absorption model for passive diffusion through biological membranes is described.
26. Briske-Anderson MJ, Finley JW, Newman SM: The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med (1997) 214(3):248-257. The inherent variability in Caco2 cell models and the need to closely monitor culture characteristics during growth and differentiation are described.
27. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 22(6):298-305. A good overview of the relationship between CYP polymorphisms and ADRs.
28. Patterson DE, Cramer RD, Ferguson AM, Clark RD, Weinberger LE: Neighborhood behavior: A useful concept for validation of 'molecular diversity' descriptors. J Med Chem (1996) 39(16):3049-3059. The principle of 'similar compounds behave similarly' in their biological properties is formalized; the basis of the neighborhood approach for modeling biological properties is also provided.
29. Horvath D, Jeandenans C: Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - A novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J Chem Inf Comput Sci (2003): in press. An analysis of the inter-relationship between structural spaces and activity spaces from an experimental receptor binding profile ('neighborhood behavoir') and the development of a formalism of 'molecular similarly principle' for characterizing drug molecules are presented.
30. Horvath D, Jeandenans C: Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - A benchmark for neighborhood behavior assessment of different in silico similarity metrics. J Chem Inf Comput Sci (2003): in press.
31. Horvath D, Mao B: Neighborhood behavior. Fuzzy molecular descriptors and their influence on the relationship between structural similarity and property similarity. Quant Struct Act Relatsh (2003): in press.
32. Horvath D: ComPharm - Automated comparative analysis of pharmacophoric patterns and derived QSAR approaches, novel tools in high throughput drug discovery. A proof of concept study applied to farnesyl protein transferase Inhibitor design. In: QSPR/QSAR Studies by Molecular Descriptors. Diudea M (Ed), Nova Science Publishers, New York, NY, USA (2001):395-439. Describes the development of a framework for incorporating conformational and structural information of target molecules relative to a reference molecule into pharmacophore descriptors, on the basis of automated, GA-driven molecular overlays of the target.
33. Paul N, Rognan D: ConsDock: A new program for the consensus analysis of protein-ligand interactions. Proteins (2002) 47(4):521-533. This paper shows how consensus scoring of several singular-docking programs is a good approach for the identification of potential hits from the protein-based virtual screening of chemical libraries.
34. Wang R, Wang S: How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci (2001) 41(5):1422-1426. A consensus scoring methodology is reviewed.
35. CEREP (Jean T, Chapelain B): Method of identification of leads or active compounds. WO-09915894 (1999). A method for selecting active compounds (leads) from libraries to facilitate drug discovery.
36. CEREP (Horvath D): Method of virtual retrieval of analogs of lead compounds. WO-09923587 (1999). A method for generating fingerprints of lead compounds and comparing those fingerprints to a virtual library.